Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways
Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways have?
Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways has 6 citations in the OpenAlex counts ScholarIQ stores.
When was Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways published?
Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways has 2023 year in the ScholarIQ index.
What is the open-access status of Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways?
Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways has hybrid oa status in the ScholarIQ index.
What is the DOI of Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways?
The DOI for Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways is on the source record.
What is the PMID of Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways?
The PMID for Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways is on the source record.
What is the OpenAlex record for Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways?
The OpenAlex for Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via theERK1/2 and p38 MAPK Signaling Pathways is on the source record.